Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anthracycline cardiotoxicity.

Robin L Jones1, Charles Swanton, Michael S Ewer

  • 1Royal Marsden Hospital, Department of Medicine, Fulham Road, London, SW3 6JJ, UK. robin.jones@icr.ac.uk

Expert Opinion on Drug Safety
|October 19, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: "On the Distinction Between Prognostic and Predictive Inference in Multicancer Early Detection" and "Interpretation of Survival Outcomes in Multicancer Early Detection Testing Requires Caution".

JCO precision oncology·2026
Same author

Assessment of human immunity to A/H3N2 influenza subclade K during 2025 emergence.

EBioMedicine·2026
Same author

Plasma signals of lung tumor promotion for molecular cancer prevention.

Cell·2026
Same author

Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation.

Nature machine intelligence·2026
Same author

Nociceptive innervation limits tertiary lymphoid structures to promote lung cancer.

Cell·2026
Same author

Subclonal immune evasion in non-small cell lung cancer.

Cancer cell·2026
Same journal

Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.

Expert opinion on drug safety·2026
Same journal

Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy.

Expert opinion on drug safety·2026
Same journal

A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension.

Expert opinion on drug safety·2026
Same journal

Tirzepatide data: safety first is safety always!

Expert opinion on drug safety·2026
Same journal

An update on the safety of biologics for the treatment of psoriasis.

Expert opinion on drug safety·2026
Same journal

Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury.

Expert opinion on drug safety·2026
See all related articles

Anthracycline chemotherapy can cause heart damage (cardiotoxicity) in patients. Understanding risk factors and monitoring left ventricular ejection fraction are key to managing this serious side effect.

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Anthracyclines are vital chemotherapy drugs but their use is limited by dose-dependent cardiotoxicity.
  • Cardiotoxicity manifests in immediate, early-onset chronic, and late-onset forms, impacting patients years after treatment.
  • Risk factors include cumulative dose, radiotherapy, age, and concurrent conditions, necessitating careful patient selection and monitoring.

Purpose of the Study:

  • To review the clinical presentation, risk factors, and management strategies for anthracycline-induced cardiotoxicity.
  • To highlight current monitoring methods and explore potential preventative and therapeutic interventions.
  • To emphasize the ongoing challenge of anthracycline cardiotoxicity in cancer survivors and adjuvant therapy.

Main Methods:

Related Experiment Videos

  • Literature review of anthracycline cardiotoxicity, risk factors, and clinical outcomes.
  • Analysis of current monitoring techniques, including left ventricular ejection fraction (LVEF) assessment.
  • Summary of established and emerging strategies for cardiotoxicity prevention and treatment.

Main Results:

  • Anthracycline cardiotoxicity presents acutely or chronically, with late-onset forms appearing years post-treatment.
  • Numerous factors influence cardiotoxicity risk, with cumulative dose being a primary concern.
  • Left ventricular ejection fraction (LVEF) is the standard monitoring tool, though other methods are not routinely employed.

Conclusions:

  • Anthracycline cardiotoxicity remains a significant clinical challenge, particularly in pediatric survivors and breast cancer patients.
  • Identifying high-risk individuals and developing novel cardioprotective strategies are crucial.
  • Continued research is needed to improve prevention and treatment of this adverse effect.